Dr. Crowe is Director of the Vanderbilt Vaccine Center and the Ann Scott Carell Professor of Pediatrics, Pathology, Microbiology, and Immunology at Vanderbilt University Medical Center. He is a board-certified pediatric infectious diseases physician and viral immunology researcher. His laboratory studies the human immune response to infection for a wide variety of major human pathogens, including many emerging infections. He is an elected member of the U.S. National Academy of Medicine and U.S. National Academy of Inventors, is an ISI Highly Cited Researcher and has been the recipient of numerous investigator awards including the Merck Future Insight Prize 2019, Golden Goose Award 2020, Harrington Prize for Innovation in Medicine 2022 and others.
Many vaccine candidates and human monoclonal antibodies developed during his team’s research have been tested in Phase I-III clinical trials in humans, including tixagevimab + cilgavimab (Evusheld) that obtained emergency approval for preventing COVID-19 and was listed as a TIME invention of 2022. He also is Founder of the biotech company IDBiologics and Chairman and Chief Scientific Officer of the nonprofit Global Pandemic Prevention and Biodefense Center, home of the AHEAD100 initiative to discover and stockpile human monoclonal antibodies for the 100 most likely causes of future epidemics.
